Compare Carvana Co (CVNA) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Recursion Pharmaceuticals Inc — how do they compare? Carvana Co trades at $63.77 (market cap $69.55B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: Carvana Co is far larger — about 32.5× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| CVNA | RXRX | |
|---|---|---|
Market Cap | $69.55B | $2.14B |
Volume | 7,671,750 | 30,789,535 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $6.79 |
52-Week Low | $56.27 | $2.84 |
Typical Hold Time | 28 Days | 22 Days |
Enterprise Value | $72.04B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $62.76, down 1.72% on the day, amid a bearish technical signal despite strong fundamental performance. The company reported robust revenue growth, with 2025 revenue reaching $20.32B and net income of $1.41B, and has consistently beaten EPS estimates in recent quarters. Analyst consensus is mixed with a $84.07 price target, while technical indicators show resistance near $64 and support at $61.
Outlook remains cautiously optimistic given operational strength and growth trajectory, but high debt levels and competitive pressures pose risks. The stock offers upside if execution continues, yet volatility and macroeconomic factors warrant careful monitoring for investors.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
